Evidence map›Paper›PMID 39289385›Full record

ArticleScientific reports2024

High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure.

Enrique Santas, Sandra Villar, Patricia Palau, Pau Llàcer, Rafael de la Espriella, Gema Miñana, Miguel Lorenzo, Gonzalo Núñez-Marín, Jose Luis Górriz, Arturo Carratalá and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Enrique Santas *Cardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Sandra Villar *Cardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Patricia PalauCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Pau LlàcerInternal Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Rafael de la EspriellaCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Gema MiñanaCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Miguel LorenzoCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Gonzalo Núñez-MarínCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Jose Luis GórrizUniversitat de València, Valencia, Spain.
Arturo CarrataláClinical Biochemistry Department, Hospital Clinico Universitario de Valencia, Valencia, Spain.
Enrique RodríguezClinical Biochemistry Department, Hospital Clinico Universitario de Valencia, Valencia, Spain.
Antoni Bayes-GenísCentro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Juan SanchisCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain.
Julio NúñezCardiology Department, Hospital Clínico Universitario, INCLIVA, Avenida Blasco Ibáñez 17, 46010, Valencia, Spain. yulnunez@gmail.com.

Funding

Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares 16/11/00403Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares 16/11/00420
6 · The paper itself

Abstract

Inflammation is relevant in the pathogenesis and progression of heart failure (HF). Previous studies have shown that elevated high-sensitivity C-reactive protein (hsCRP) are associated with greater severity and may be associated with adverse outcomes. In this study, we sought to evaluate the prognostic role of hsCRP in a non-selected cohort of patients with acute HF. We prospectively included a multicenter cohort of 3,395 patients following an admission for acute HF. HsCRP levels were evaluated during the first 24 h following admission. Study endpoints were the risks of all-cause mortality, CV-mortality, and total HF readmissions. The mean age was 74.2 ± 11.2 years and 1,826 (53.8%) showed a left ventricular ejection fraction (LVEF) ≥ 50%. Median hsCRP was 12.9 mg/L (5.4-30 mg/L). Over a median follow-up of 1.8 (0.6-4.1) years, 1,574 (46.4%) patients died, and 1,341 (39.5%) patients were readmitted for worsening HF. After multivariable adjustment, hsCRP values were significantly and positively associated with a higher risk of all-cause and CV mortality (p = 0.003 and p = 0.001, respectively), as well as a higher risk of recurrent HF admissions (p < 0.001). These results remained consistent across important subgroups, such as LVEF, sex, age, or renal function. In patients with acute HF, hsCRP levels were independently associated with an increased risk of long-term death and total HF readmissions.

Indexed as

C-Reactive ProteinHeart FailureAcute DiseaseAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPatient ReadmissionPrognosisProspective StudiesRisk FactorsBiomarkersC-Reactive ProteinC-reactive proteinHeart failureHospitalizationsInflammationMortalityPrognosis

Identifiers

PMID39289385
PMCPMC11408489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.